Literature DB >> 15946342

Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus.

Paola Iannetti1, Alberto Spalice, Pasquale Parisi.   

Abstract

We report on an 11-year healthy boy who presented refractory status epilepticus (SE), which was unresponsive to conventional antiepileptic drugs used in the algorithm of the treatment of SE. Based on evidence that verapamil has anticonvulsant activity in animal models and the fact that the boy had a supraventricular tachycardia (140-160 b/min), i.v. verapamil (0.034 mg/min) was administered on day 37, and after a 3.125 mg cumulative verapamil dose (1.5 hour after initiation of the infusion), the patient regained consciousness was able to breathe spontaneously and the electrical SE promptly disappeared. The apparent dramatic response to i.v. verapamil may be explained by its direct anticonvulsant action on the basis of the potential involvement of calcium channels in epileptic activity and that verapamil, a known Pgp inhibitor in the cerebrovascular endothelium in the epilepticus focus, acted by facilitating the brain penetration of the antiepileptic drugs that our patient was receiving simultaneously.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946342     DOI: 10.1111/j.1528-1167.2005.59204.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  28 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 2.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

3.  Status epilepticus.

Authors:  Panayiotis N Varelas; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

4.  Targeting anti-epileptic drug therapy without collateral damage: nanocarrier-based drug delivery.

Authors:  Marvin A Rossi
Journal:  Epilepsy Curr       Date:  2012-09       Impact factor: 7.500

Review 5.  Status epilepticus: an update.

Authors:  Panayiotis N Varelas; Marianna V Spanaki; Marek A Mirski
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

Review 6.  Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy.

Authors:  Hadas Han; Aniv Mann; Dana Ekstein; Sara Eyal
Journal:  AAPS J       Date:  2017-05-26       Impact factor: 4.009

Review 7.  Literature review, case report, and expert discussion of prolonged refractory status epilepticus.

Authors:  T K Robakis; L J Hirsch
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

8.  Multidrug resistance proteins expression in glioma patients with epilepsy.

Authors:  Chiara Calatozzolo; Bianca Pollo; Andrea Botturi; Loredana Dinapoli; Mariantonia Carosi; Andrea Salmaggi; Marta Maschio
Journal:  J Neurooncol       Date:  2012-07-26       Impact factor: 4.130

Review 9.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain.

Authors:  R Clinckers; I Smolders; Y Michotte; G Ebinger; M Danhof; R A Voskuyl; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-10-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.